Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity
may be important in growth and survival of some types of cancer. This Phase I trial is
studying the safety, side effects, and best dose of SGX523 when given to patients with
advanced cancer, and how well it inhibits MET activity in tumors.